Luna LifeSci Advisors

Luna LifeSci Advisors consults across the NAMs ecosystem, helping MPS developers grow and scale novel platforms, and guiding pharma and CROs to evaluate, adopt, and integrate MPS technologies into preclinical workflows. Our 25+ years of expertise spans strategy, technology development, platform validation, workflow integration, regulatory alignment, fundraising, company building, and commercial execution.
Frontier Bio Corporation

Frontier Bio creates bioprinted 3D human models (BBB, lung, vasculature) to improve clinical translation and reduce reliance on animal testing.
Nagi Bioscience

We are a Swiss high-tech company developing and offering cutting-edge biological testing solutions that enable scientists to generate insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our technologies are designed to integrate seamlessly into existing lab environments, enhancing efficiency, accuracy, and reproducibility.
Exir Bio

Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies

We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
Ncardia

For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC).
SynVivo, Inc.

Organ-on-Chip models from SynVivo recreate complex microvasculature including scale, morphology, hemodynamic shear stress, and cellular interactions in a perfused microfluidic chip environment. Validated models include Air Liquid Interface for Lung, Blood-Brain Barrier, Tumor, DIVI, Inflammation.
Hesperos Inc.

Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
MIMETAS

Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.